Fluidigm (South San Francisco, California) says it is continuing its strategy of delivering disruptive single-cell analysis capabilities to life science researchers around the world through its planned acquisition of DVS Sciences (Sunnyvale, California). The transaction will create a "single-cell technology powerhouse," the company said.